BioSpace News Archive

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that six abstracts have been accepted for presentation at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place virtually from December 5 to 8, 2020.

Avidea Technologies, Inc., a private biotechnology company developing immunotherapies through innovations in polymer-drug conjugate technologies, announced today the publication of preclinical studies in Nature Immunology showing how route of vaccine administration imprints on the quality of anticancer T cell responses that affect treatment efficacy.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that data from two of its clinical programs have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5 – 8, 2020

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company’s clinical and research portfolio have been accepted for oral presentations and two abstracts have been accepted for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually December 5-8, 2020.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one abstracts have been selected for virtual presentation, including two oral presentations, at the upcoming American Society of Hematology (ASH) 2020 Annual Meeting taking place December 5-8, 2020.

Curis, Inc. announced that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the 62nd American Society of Hematology Annual Meeting and Exposition which will be held virtually from December 5-8, 2020.

MannKind Corporation reported financial results for the quarter and nine months ended September 30, 2020.

The Planet Group (“Planet”), a leading provider of outsourced human capital and consulting solutions and a portfolio company of MidOcean Partners, announced today that it has entered into an agreement to acquire NDA Partners, a global life sciences management consulting and contract development organization focused on providing innovative product development and regulatory services to the pharmaceutical, biotechnology and medical device industries

LeMaitre Vascular, Inc. announced that it is participating in two investor conferences in November.